MARLBOROUGH, Mass.,
Jan. 12, 2016 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) today announced the U.S. and
European launch of the LithoVue™ Single-Use Digital Flexible
Ureteroscope for minimally invasive endoscopic procedures to
diagnose and treat stones and other conditions of the kidney,
ureter and bladder. By providing a single-use flexible ureteroscope
for urologists, the LithoVue System is designed to address the
inconsistent performance,1-4
operational challenges and costs associated with widely used
reusable scopes that require maintenance, sterilization and
reprocessing.1-7
Experience the interactive Multimedia News Release here:
http://www.multivu.com/players/English/7223459-boston-scientific-lithovue/
The LithoVue System is designed to deliver high-quality digital
visualization and seamless navigation for consistent clinical
performance during each patient procedure. Unlike reusable
ureteroscopes, the LithoVue System can overcome the common
challenges of unpredictable scope repairs and maintenance,
reprocessing, sterilization and degradation of scope performance
over time. The LithoVue System eliminates many of the
inefficiencies and financial costs of ownership for reusable
ureteroscopes, such as:
- On average, new digital flexible ureteroscopes require repair
after fewer than 12 uses and cost more than $6,000 per
repair.5,6
- Procedural delays are often due to reprocessing and repairs,
and on average occur several times per day at a cost of
$830 per
delay.8-10
- Hospitals can eliminate many of the steps required to use,
maintain and handle a reusable
ureteroscope.11
"Flexible ureteroscopy is considered the gold standard for
treating many stones in the ureter and kidney, and the LithoVue
System provides high-quality visualization that is comparable to or
better than the leading digital reusable ureteroscopes," said
Glenn M. Preminger, M.D., Professor
of Urologic Surgery and director of the Duke
University Comprehensive Kidney Stone Center. "We
believe that the LithoVue System offers a safe, effective and
affordable solution that helps to avoid many of the hassles and
unpredictable challenges of reusable ureteroscopes, without
compromising visualization or maneuverability."
The LithoVue System features:
- High-resolution images: A digital CMOS imager in the
7.7F tip, with a working distance of 2mm–50mm, produces superb
quality images across a depth of field that is equivalent to or
better than those from other commonly used reusable scopes on the
market.12
- Seamless navigation: Full 270 degree scope deflection in both
directions provides accurate navigation toward the targeted
treatment area.
- All-in-one solution: The LithoVue workstation monitor
with integrated image processing software is mounted on a compact,
rolling mobile cart which can be used alone during a ureteroscopic
procedure or connected to existing monitors and integrated video
systems in the operating room suite.
"At Boston Scientific, we are committed to providing innovative
solutions to the healthcare challenges that our customers face
every day," said Karen Prange,
senior vice president and president, Urology and Pelvic Health,
Boston Scientific. "The LithoVue System is an example of how we are
focused on addressing unmet needs by providing urologists and
hospitals a predictable, cost-effective, minimally invasive
endoscope for the management of kidney stones."
The LithoVue System is now available in the U.S., Europe and New
Zealand. For more product and important safety information,
please visit: www.bostonscientific.com/lithovue. Or follow Boston
Scientific Urology and Pelvic Health on Twitter at
@bsc_urology.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for more than 35 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding our product
launches and product performance and impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; the
closing and integration of acquisitions; intellectual property;
litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, which we may update in Part II, Item 1A –
Risk Factors in Quarterly Reports on Form 10-Q we have filed
or will file hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS
Media:
Tom Keppeler
508-683-6585 (office)
Media Relations
Boston Scientific Corporation
thomas.keppeler@bsci.com
Simonetta Balbi
+39 3387936422 (mobile)
+39 0106060281 (direct)
Media Relations – Europe
Boston Scientific Corporation
balbis@bsci.com
Investors:
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
- Mues AC, Knudsen BE. Evaluation of 24 holmium: YAG laser
optical fibers for flexible ureteroscopy. J Urol. 2009;182:
348-54.
- Carey RI, Gomez CS, Maurici G, et al. Frequency of
ureteroscope damage seen at a tertiary care center. J Urol.
2006;176:607-10.
- Collins JW, Keeley FX, Timoney A.
Cost analysis of flexible ureterorenoscopy. Br J
Urol. 2004;93(7):1023-6.
- Carey RI, Martin CJ, Knego JR. Prospective evaluation of
refurbished flexible ureteroscope durability seen in a large public
tertiary care center with multiple surgeons. Urology.
2014;84:42-5.
- Shah K, Monga M, Knudsen B. Prospective randomized trial
comparing 2 flexible digital ureteroscopes: ACMI/Olympus Invisio
DUR-D and Olympus URF-V. Urology.
2015;85(6):1267-71.
- Knudsen BE, Ferraro M. Digital video flexible ureteroscopy:
GyrusACMI/Olympus Invisio®DUR®-D twelve month failure and repair
experience. NCS 2009.
- Knudsen B, Miyaoka R, Shah K, et al. Durability of the
next-generation flexible fiberoptic ureteroscopes: A randomized
prospective multi-institutional clinical trial.
Urology.2010;75:534-9.
- Macario A. Editorial. What does one minute of operating room
time cost? J Clin Anesth. 2010;22:233-6.
- United States Bureau of Labor Statistics. Consumer Price Index.
Medical Care Services. June 30,
2015.
- Hession SM. Endoscope disinfection by orthophthalaldehyde in a
clinical setting: An evaluation of reprocessing time and costs
compared with glutaraldehyde. Gastroenterol Nurs.
2003;26(3):110-4.
- Value Vantage. Day-in-the-Life Research, May 2014.
- Eisner B. Evaluating the image quality of a novel single-use
digital flexible ureteroscope. J Endourol.
2015;29(1):A348.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-launches-the-lithovue-single-use-digital-flexible-ureteroscope-in-us-and-europe-300202203.html
SOURCE Boston Scientific Corporation